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Abstract: The kallikrein-kinin system is well known for its role in pain and  inflammation, and 
has been shown recently by our group to have a role also in the regulation of energy  expenditure. 
We have demonstrated that B1 receptor knockout (B1KO) mice are resistant to obesity induced 
by a high-fat diet (HFD) and that B1 receptor expression in adipocytes regulates glucose toler-
ance and predisposition to obesity. However, it is also known that in the absence of B1 receptor, 
the B2 receptor is overexpressed and can take over the function of its B1 counterpart, rendering 
uncertain the role of each kinin receptor in these metabolic effects. Therefore, we investigated 
the impact of ablation of each kinin receptor on energy metabolism using double kinin receptor 
knockout (B1B2KO) mice. Our data show that B1B2KO mice were resistant to HFD-induced 
obesity, with lower food intake and feed efficiency when compared with  wild-type mice. They 
also had lower blood insulin and leptin levels and higher glucose tolerance after treatment with 
an HFD. Gene expression for tumor necrosis factor-alpha and C-reactive protein, which are 
important genes for insulin resistance, was reduced in white adipose tissue, skeletal muscle, and 
the liver in B1B2KO mice after the HFD. In summary, our data show that disruption of kinin 
B1 and B2 receptors has a profound impact on metabolic homeostasis in mice, by improving 
glucose tolerance and preventing HFD-induced obesity. These novel findings could pave the 
way for development of new pharmacological strategies to treat metabolic disorders such as 
insulin resistance and obesity.
Keywords: kallikrein-kinin system, B1/B2 receptors, obesity, glucose tolerance, insulin 
resistance
Introduction
Obesity and diabetes are serious health problems that are of particular concern given 
their increasing incidence around the world. The World Health Organization  estimates 
that at least 2.8 million people die each year as a result of being overweight or obese, 
and currently more than 1.4 billion adults are overweight.1 The excess energy intake 
in obese individuals is stored as fat tissue, which is an  important organ in the regu-
lation of metabolic homeostasis.2 In this scenario, obesity and  diabetes are closely 
related since the accumulation of adipose tissue alters the pattern of  secretion of mol-
ecules involved in physiological processes, such as glucose uptake, lipid metabolism, 
inflammation, and vascular homeostasis,3,4 which may lead to insulin resistance and 
development of diabetes.
Study of the kallikrein-kinin system (KKS) has contributed to our understanding of 
many biological processes, including inflammation, nociception, vascular  permeability, 
blood pressure regulation, and smooth-muscle contraction and relaxation.5,6 
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
400
Morais et al
The KKS consists of distinct enzymes called kallikreins, 
which cleave their precursors, kininogens,  producing kinins, a 
small group of peptides. Kinins activate two specific G-protein 
coupled receptors, ie, B1 and B2. Although it has been known 
since 1932 that the KKS participates in energy metabolism,7 
it has only been recently that these  mechanisms have started 
to be elucidated.8,9 Several studies have highlighted the role 
of the B2 receptor in glucose homeostasis, in particular its 
effects on insulin-mediated glucose uptake.10,11 It was also 
shown that B1 receptor blockade by a specific antagonist 
could prevent hyperglycemia and insulitis,  demonstrating that 
not only the B2 receptor but also the B1 receptor participates 
in the regulation of glucose uptake.12
More recently, the participation of the B1 receptor in 
insulin secretion has been demonstrated,13 as well as in 
the secretion of leptin by adipose tissue.14 More evidence 
concerning the role of KKS in metabolism came from 
B1 receptor knockout (B1KO) mice which were shown to be 
hypersensitive to leptin and resistant to obesity induced by 
a high-fat diet (HFD).15,16 Moreover, overexpression of the 
B1 receptor in adipocytes demonstrated that this receptor 
regulates glucose tolerance and determines predisposition 
to obesity.17 In agreement with these observations, recent 
findings have highlighted the inflammatory role of the 
B1 receptor in insulin-resistant glucose-fed rats, in which 
 several pathological symptoms were reversed by treatment 
with specific B1 receptor antagonists.18,19
We can infer from the above data that KKS participates in 
development of obesity and related diseases, including insulin 
resistance and type 2 diabetes. However, the role played by 
each kinin receptor in these processes remains unclear, given 
the recurring evidence that in the absence of one receptor, the 
other is overexpressed and can compensate its functions.20,21
Therefore, we investigated energy metabolism in 
mice with deletion of both kinin receptors (B1B2KO). 
We found that B1B2KO mice had lower food and energy 
intake, lower feed efficiency, and lower serum insulin and 
leptin levels when compared with wild-type (WT) control 
mice.  Hypothalamic mRNA expression of genes related to 
regulation of food intake and metabolism was unchanged in 
B1B2KO mice. However, when these mice were subjected 
to an HFD, they showed increased glucose tolerance when 
compared with their WT control littermates. The tumor 
necrosis  factor-alpha (TNF-α) and C-reactive protein (CRP) 
genes code for pro-inflammatory proteins that are also known 
for their role in insulin resistance, and show reduced mRNA 
 expression in white adipose tissue, skeletal muscle, and the liver. 
These novel data suggest that B1 and B2 receptors have 
pivotal roles in energy balance by controlling glucose 
homeostasis and may be targets for insulin resistance and 
diabetes therapy.
Materials and methods
animals
Healthy 12-week-old C57Bl/6 male B1B2KO mice and their 
WT littermates were used in this study. They were obtained 
from the animal house at Universidade Federal de São Paulo, 
São Paulo, and maintained on a 12-hour light/12-hour dark 
cycle at 22°C, with free access to standard chow and drink-
ing water. The experimental protocols were approved by the 
institutional ethics committee (01730/08).
genotyping of kinin B1 and B2  
knockout mice
Genomic DNA was isolated from a mice tail fragment using 
an NaOH extraction protocol.22 Kinin B1 and B2 recep-
tors were amplified by polymerase chain reaction (PCR) 
using the following primers: B1 receptor (NM_007539.2) 
sense 5′-TGAAGCTGTGAGCTCTTTG-3′ and antisense 
5′-GCTACCCAGATGAGCAGGCA-3′; B2 (NM_009747.2) 
receptor sense 5′-TGTCCTCAGCGTGTTCTTCC-3′ and 
antisense 5′-GGTCCTGAACACCAACATGG-3′.
Kinin B1 and B2 receptor function
The functionality of B1 and B2 receptors was assayed by  testing 
the contractile response of smooth muscle strips (from the 
 fundus of the stomach) to bradykinin and des-Arg(9)-bradykinin 
(Bachem Inc.). Briefly, smooth muscle strips were extracted 
from the mice and kept at 37°C in oxygenated (95% O
2
, 5% 
CO
2
) modified Krebs buffer (119 NaCl mM, 4.7 KCl mM, 1.2 
MgSO
4
:7H
2
O mM, 2.5 CaCl
2
:2H
2
O mM, 1.2 KH
2
PO
4
 mM, 
25.0 NaHCO
3
 mM, and 5.5 glucose mM). After an  equilibration 
period of 45–60 minutes at a resting tension of 0.5 g, experi-
ments were initiated by checking the viability of the prepared 
specimen by exposure to carbachol ( Sigma-Aldrich) at 10-5 
M. Kinin agonists, ie, bradykinin 10-6 M and Des-Arg(9)-
bradykinin,10-6 M), were then applied, and the  contractile 
responses were recorded using an isometric transducer 
(TRI202P, Panlab) connected to a computerized system for data 
acquisition and analysis ( PowerLab, AD Instruments).
Treatment with a high-fat diet
Mice were fed ad libitum for 12 weeks with a control 
diet (10% kcal from fat) or an HFD (45% kcal from fat) 
from Research Diets Inc. Each mouse was put in an indi-
vidual cage, with weekly weight and food intake recording. 
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After treatment, the mice were euthanized for blood and 
tissue  collection. Feed efficiency was calculated by the ratio 
of total weight gain and calories of food ingested in both WT 
and B1B2KO mice after treatment with the HFD.
leptin and insulin serum levels
Serum samples were separated and used for leptin (R&D 
Systems) and insulin (Millipore) measurement as specified 
by the manufacturers.
glucose tolerance test
Mice were fasted for 8 hours before the glucose tolerance test. 
A small fragment of tail tissue was cut for blood collection 
and glucose was quantified using an Advantage II glucometer 
(Roche). Glucose measurements were carried out before and 
at 15, 30, 60, and 120 minutes after intraperitoneal injection 
of glucose 1 g/kg body weight.
insulin and leptin sensitivity test
For the insulin sensitivity test, 0.01 U/kg of recombinant 
human insulin (Lilly) was injected intraperitoneally. Glucose 
levels were assessed in blood collected from the tail before and 
15, 30, and 60 minutes after insulin injection immediately after 
treatment with the HFD. For leptin sensitivity, recombinant 
mouse leptin (R&D Systems) was injected as an intraperitoneal 
bolus of 40 µg/day for 5 days, with food intake measured under 
basal conditions. Food intake  measured 5 days before the leptin 
injections was considered as basal consumption.
gene expression
Total RNA (2 µg) was extracted from the hypothalamus, white 
adipose tissue, skeletal muscle, and liver from WT and B1B2KO 
mice using TRIzol Reagent (Invitrogen). It was reverse-
 transcribed using M-MLV (Invitrogen) to cDNA following 
the manufacturer’s instructions. The product was amplified by 
real-time PCR using the SYBR Green ( Fermentas)  protocol. 
 Prolylcarboxipeptidase (PRCP), melanocortin 4  receptor 
(MC4R),  neuropeptide Y (NPY),  agouti-gene-related 
 protein (AgRP),  pro-opiomelanocortin (POMC), cocaine- 
and  amphetamine-regulated  transcript (CART), leptin, 
TNF-α, and CRP mRNAs were quantified as a relative value 
 compared with the internal reference, β-actin. Primers used 
for  real-time PCR were as follows: PRCP (NM_001278581.1) 
sense 5 ′-CAGGAGCTCAAGGTCAACCTGTC-3 ′ 
a n d  a n t i s e n s e  5 ′ - G A AC C ATAC C AT C A AG C T 
G C C AG AT- 3 ′ ;  M C 4 R  ( N M _ 0 1 6 9 7 7 . 4 )  s e n s e 
5′-GCTGTGGCAGATATGCTGGTGAG-3′ and antisense 
5 ′-CGAGCAAGGAGCTACAGATCACAG-3 ′; NPY 
(NM_023456.2) sense 5′-CGCTCTGCGACACTACAT 
CAA-3′ and antisense 5′-GGGCTGGATCTCTTGCCAT-3′; 
AgRP (NM_001271806.1) sense 5′-GGTGCTAGATC CACA 
GAACCG-3′ and antisense 5′-CCAAGCAGGACTCGT 
G C AG - 3 ′ ;  P O M C  ( N M _ 0 0 1 2 7 8 5 8 1 . 1 )  s e n s e 
5 ′ -CGAGGCCTTTCCCCTAGAGT-3 ′  and  an t i -
sense 5 ′-CCAGGACTTGCTCCAAGCC-3 ′; CART 
(NM_013732.7) sense 5′-TGGATGATGCGTCCCATGA-3′ 
and antisense 5′-CGGAATGCGTTTACTCTTGAGC-3′; 
leptin (NM_008493.3) sense 5 ′-AGCATTCAGG 
GCTAACATCC-3 ′ and antisense 5′-TATCCGCCA 
AGCAGAGGGT-3 ′; TNF-α (NM_013693.3) sense 
5′-CACCACGCTCTTCTGTCTAC-3′ and antisense 5′-GA 
TCTGAGTGTGAGGGTCTGG-3′; CRP (NM_007768.4) 
sense 5′-GGAGAAGCTACTCTGGTGCCTTCT-3′ and 
antisense 5′-CACACAGTAAAGGTGTTCAGTGGCT-3′, 
and β-actin (NM_007393.3) sense 5′- GAACCCTAAGGC 
CAACCGTGAA-3′ and antisense 5′- GACCAGAGGCAT 
ACAGGGACAAC-3′. Quantitative values for mRNA 
 expression were obtained by the parameter 2-∆Ct, in which 
∆Ct represents the subtraction of the β-actin Ct values from 
the ones of the target gene.
Treatment with kinin B1 and B2  
receptor antagonists
Healthy 12-week-old male C57Bl/6 mice were injected intra-
peritoneally daily for 7 days with the B1 receptor antagonist 
R-715 (1 mg/kg) together with the B2 receptor antagonist 
HOE-140 (500 µg/kg) or vehicle (saline). Both antagonists 
were obtained from Bachem Inc. After treatment, the mice 
in both groups were euthanized and their tissues collected for 
analysis of leptin, CRP, and TNF-α gene expression.
Statistical analysis
The results are reported as the mean ± standard error of the 
mean. Statistically significant differences in mean values 
were evaluated by the independent Student’s t-test when two 
groups were compared, or by the ANOVA test when three or 
more groups were analyzed. A P-value #0.05 was considered 
to be statistically significant.
Results
genetic and pharmacological assays  
for kinin B1 and B2 receptors
Deletion of both kinin receptors in the mice was confirmed 
by PCR genotyping, as demonstrated in Figure 1. In the DNA 
samples from WT mice, B1 (Figure 1A) and B2 receptor 
(Figure 1B) gene fragments were amplified by PCR, whereas 
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in B1B2KO mice the fragments could not be amplified. The 
pharmacological functionality of the B1 and B2 receptors 
was assayed by testing the contractile response of smooth 
muscle strips from the gastric fundus to bradykinin and des-
Arg(9)-bradykinin. WT mice preparations were responsive 
to carbachol and to B1 and B2 receptor agonists (Figure 1C). 
On the other hand, double knockout mice were responsive 
to carbachol but not to the kinins (Figure 1D), confirming 
the absence of B1 and B2 receptors in this genetic mouse 
model.
B1B2KO mice protected against  
hFD-induced obesity
Body weight was measured for 12 weeks in B1B2KO mice 
on a control diet or the HFD. The mice had a reduced body 
weight and smaller visceral fat depots after the HFD but not 
after the control diet (Figure 2A and B). To investigate why 
B1B2KO mice were protected against HFD-induced weight 
gain, food and energy intake was measured every week dur-
ing the HFD and chow diet regimen. As shown in Figure 2C 
and D, WT mice showed higher food intake and calories 
ingested when compared with B1B2KO mice regardless of 
the type of diet. Also, the B1B2KO mice on the HFD showed 
lower feeding efficiency (Figure 2E), indicating more energy 
expenditure after the HFD.
gene expression in the hypothalamus 
was unchanged in B1B2KO mice
Given the reduced food and energy intake found in the B1B2KO 
mice, we also investigated the mRNA expression of important 
hypothalamic genes associated with satiety and energy balance. 
However, expression of orexigenic (NPY, AgRP), anorexigenic 
(POMC, CART), PRCP, and MC4R genes was not significantly 
different between B1B2KO and WT mice treated with a control 
diet or the HFD (data not shown).
insulin and leptin levels were reduced  
in B1B2KO mice
In order to better understand the metabolic profile in B1B2KO 
mice, we measured two important hormones involved in 
energy homeostasis, ie, insulin and leptin. Insulin and leptin 
levels (protein in the serum and mRNA from white adipose 
tissue) were decreased in B1B2KO mice when compared with 
WT mice using both regimens (Figure 3A–C). No difference 
in leptin sensitivity was observed in B1B2KO mice after the 
HFD (Figure 3D). Also, B1B2KO mice on the control diet 
or HFD did not present changes in insulin sensitivity when 
compared with WT mice (Figure 3E).
B1B2KO mice showed improved  
glucose tolerance
Differences in insulin levels between B1B2KO and WT mice 
suggested a potential impact of the B1 and B2 receptors on 
blood glucose levels and glucose tolerance. B1B2KO mice 
showed lower glucose levels than WT mice after treatment 
with the HFD (Figure 4A). Accordingly, in this condition, 
B1B2KO mice also showed higher glucose tolerance after 
glucose stimulation (Figure 4B).
genes related to insulin resistance were 
downregulated after hFD
Given the importance of inflammation in the pathogenesis 
of insulin resistance, we measured the expression of two 
inflammatory mediators in different metabolic tissues of 
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Figure 1 genotyping the kinin B1 and B2 receptor in B1B2KO mice.
Notes: (A) B1 and (B) B2 receptor gene fragments were amplified by polymerase chain reaction. The contractile response of smooth muscle strips from the gastric fundus 
to cch (positive control), BK, and DBK in (C) WT and (D) B1B2KO mice.
Abbreviations: BK, bradykinin; DBK, des-arg(9)-bradykinin; n, negative control; WT, wild-type; B1B2-/-, B1B2KO; cch, carbachol.
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double knockout mice. TNF-α mRNA expression was 
reduced in both white adipose tissue and skeletal muscle in 
B1B2KO mice after the HFD (Figure 5A and B). Similarly, 
CRP mRNA expression was decreased in the livers of the 
B1B2KO mice after the HFD (Figure 5C). In addition, WT 
mice were treated for 7 days with specific B1 (R-715) and B2 
(HOE-140) receptor antagonists. Gene expression of leptin 
and TNF-α in white adipose tissue and skeletal muscle was 
measured and CRP expression was evaluated in the liver, but 
no differences were observed (data not shown).
Discussion
Using both genetic and pharmacological approaches, the role 
of kinin receptors in energy balance has started to be eluci-
dated in recent years. However, it is known that when one of 
the kinin receptors is blocked or deleted, the other  receptor 
0
20
50 0
40
80
120
160
200
240
280
320
70
90
110
130
150
25
30
35
WT control
WT HFD
B1B2KO HFD
B1B2KO
WT
B1B2KO
WT
B1B2KO
WT
B1B2KO control
WT control
WT HFD
B1B2KO HFD
B1B2KO control
40
45
A
C
E
D
B
1 2 3 4 5 6 7 8 9 10 11 12
Control dietWeeks
1 2 3 4 5 6 7 8 9 10 11 12
0
0.015
0.03
0.045
0.06
#
#
# #
# #
# #
#
#
**
*
*
*
**
*
*
*
*
*
*
*
*
*
Weeks
W
ei
g
h
t 
(g
)
V
is
ce
ra
l f
at
 (
g
)
C
u
m
u
la
ti
ve
 f
o
o
d
 in
ta
ke
 (
g
)
F
ee
d
 e
ff
ic
ie
n
cy
 (
g
/k
ca
l)
E
n
er
g
y 
in
ta
ke
 (
kc
al
)
HFD
Control diet HFD
Control diet HFD
0
0.5
1
1.5
2
2.5
3.5
3
Figure 2 B1B2KO mice are protected against obesity induced by HFD treatment and present lower food intake and feed efficiency.
Notes: (A) Body weight after 12 weeks of hFD treatment. *P,0.05 WT hFD versus B1B2KO groups; #P,0.05 versus all groups. Data are expressed as the mean ± standard 
error of the mean and represent mouse weight per gram. White circles indicate WT control, black circles indicate WT hFD, white triangles indicate B1B2KO control, 
and black triangles indicate B1B2KO hFD. (B) Visceral fat weight after 12 weeks of hFD treatment. White bars indicate WT control and hFD, and black bars indicate 
B1B2KO control and hFD. #P,0.05 WT hFD versus WT control; **P,0.01 WT hFD versus B1B2KO hFD. Data are expressed as the mean ± standard error of the 
mean and represent visceral fat depot weight per gram. (C) energy intake after 12 weeks of hFD treatment. energy intake was calculated based on information from the 
chow manufacturer. White circles indicate WT control, black circles indicate WT hFD, white triangles indicate B1B2KO control, and black triangles indicate B1B2KO hFD. 
*P,0.05 WT hFD versus B1B2KO hFD; #P,0.05 WT control versus B1B2KO control. Data are expressed as the mean ± standard error of the mean and represent energy 
intake (kcal). (D) cumulative food intake after 12 weeks of hFD treatment. White bars indicate WT control and hFD, black bars indicate B1B2KO control and hFD. 
*P,0.05 WT control versus B1B2KO control; #P,0.05 WT hFD versus B1B2KO hFD. Data are expressed as the mean ± standard error of the mean and represent chow 
per gram. (E) Feed efficiency after 12 weeks of HFD treatment. Feed efficiency was calculated by the ratio of total weight gain and calories of food ingested after the HFD 
treatment in both WT and B1B2KO mice. White bars indicate WT control and hFD, black bars indicate B1B2KO control and hFD. P,0.01 WT hFD versus control diet 
group. **P,0.01 WT hFD versus B1B2KO hFD. Data are expressed as the mean ± standard error of the mean and represent energy intake (kcal). 
Abbreviations: hFD, high-fat diet; WT, wild-type.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
404
Morais et al
0
120
110
100
90
80
70
60
16
0 0
0.02
0.04
0.06
0.08
0.75
1.5
2.25
3
32
L
ep
ti
n
 (
p
g
/m
L
)
F
o
o
d
 in
ta
ke
 %
In
su
lin
 (
n
g
/m
L
)
L
ep
ti
n
 (
m
R
N
A
)
48
64
A B C
D E
B1B2KO
*
*
*
*
*
**
**
WT
B1B2KO
WT
B1B2KO
WT B1B2KO
WT
Control diet HFD
0 0 15 30 601 2 3 4 5
50
75
100
125
150
175
200
Control diet
Days Time (minutes)
G
ly
ce
m
ia
 (
m
g
\d
L
)
HFD Control diet HFD
# #
WT control
WT HFD
B1B2KO HFD
B1B2KO control
Figure 3 B1B2KO mice have low insulin and leptin levels.
Notes: (A) Serum leptin levels after 12 weeks of hFD treatment. (B) Serum insulin levels after 12 weeks of hFD treatment. (C) leptin mrna expression in white adipose 
tissue after 12 weeks of hFD treatment. White bars indicate WT control and hFD, and black bars indicate B1B2KO control and hFD. *P,0.05 B1B2KO control versus WT 
control; **P,0.01 B1B2KO hFD versus WT hFD; #P,0.05 WT hFD versus WT control. (D) leptin sensitivity test in WT and B1B2KO mice. consumption was measured 
after intraperitoneal injection of 40 µg/day of leptin and compared with basal consumption. Data are expressed as the mean ± standard error of the mean and represent 
percentage of food intake. White squares indicate WT, black squares indicate B1B2KO. (E) insulin sensitivity test after 12 weeks of hFD treatment. glycemia was measured 
before and after intraperitoneal injection of insulin 0.01 U/kg at following the times: 0, 15, 30, and 60 minutes. Data are expressed as the mean ± standard error of the mean. 
White circles indicate WT control, black circles indicate WT hFD, white triangles indicate B1B2KO control, and black triangles indicate B1B2KO hFD. *P,0.05 WT hFD 
versus all groups.
Abbreviations: hFD, high-fat diet; WT, wild-type.
0 125
200
275
350
425
500
50
100
150
200
250
A B
Control diet
Time (minutes)
G
ly
ce
m
ia
 (
m
g
/d
L
)
B
lo
o
d
 g
lu
co
se
 (
m
g
/d
L
)
HFD 0 15 30 60 120
WT control
WT HFD
B1B2KO HFD
B1B2KO control
B1B2KO *
*
#
WT
Figure 4 B1B2KO mice show high glucose tolerance.
Notes: (A) glucose levels after 12 weeks of hFD treatment. White bars indicate WT control and hFD, black bars indicate B1B2KO control and hFD. *P,0.05 WT hFD 
versus B1B2KO hFD. (B) glucose tolerance test after 12 weeks of hFD treatment. glycemia was measured before and after intraperitoneal injection of glucose 1 g/kg at the 
following times: 0, 15, 30, 60, and 120 minutes. Data are expressed as the mean ± standard error of the mean. White circles indicate WT control, black circles indicate WT 
hFD, white triangles indicate B1B2KO control, and black triangles indicate B1B2KO hFD. *P,0.05 WT hFD versus all groups and #P,0.05 WT hFD versus B1B2KO hFD. 
Abbreviations: hFD, high-fat diet; WT, wild-type.
may compensate by upregulating its expression, which may 
introduce a confounding factor when  interpreting data. To 
resolve part of this issue, B1B2KO mice were generated 
and characterized. These double knockout mice are healthy, 
 fertile, normotensive, and protected against endotoxin-
induced hypotension.23
In our present work, we have shown that B1B2KO mice 
are resistant to HFD-induced obesity, showing less food intake 
and a smaller weight gain per calorie intake when compared 
with WT mice. Based on these observations, we analyzed the 
mRNA expression of genes in the hypothalamus associated 
with metabolism. NPY and AgRP, both orexigenic genes, 
were found to be present at the same levels in B1B2KO and 
WT mice whether on the control diet or the HFD. Similarly, 
expression of anorexigenic genes, POMC and CART, was 
not different between knockout and control mice. Recently, 
our group found that CART mRNA expression is elevated in 
the lateral hypothalamic area of B1KO mice.24 Even though 
B1KO and B1B2KO mice show similarities in some aspects 
of metabolism, expression of CART seems to be different in 
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the two strains. However, it should be taken into account that 
we analyzed expression of CART in the whole hypothalamus 
of B1B2KO mice, and not only in the lateral hypothalamic 
area, which may have contributed to the observed lack 
of differences. Further, Heijboer et al demonstrated that 
gene expression for NPY, AgRP, POMC, and CART is not 
altered in the mouse hypothalamus after treatment with an 
HFD,25 suggesting that regulation of these genes may be not 
affected by an HFD in WT or B1B2KO mice. PRCP and 
MC4R gene expression was also tested, given the role of 
these genes in metabolism. PRCP is an enzyme associated 
with inactivation of alpha-melanocortin-stimulating hormone 
in rodents,26 which in turn binds to MC4R to regulate food 
intake behavior and energy balance.27 Together with other 
orexigenic and anorexigenic genes, expression of PRCP and 
MC4R was unchanged in the B1B2KO mouse hypothalamus 
after treatment with the control diet or the HFD, indicating 
that the reduced food consumption observed in these mice 
was probably related to an alternative metabolic pathway not 
examined in this study.
Circulating levels of leptin and insulin were also  measured 
in the B1B2KO and WT mice. Decreased serum levels of 
both hormones were found in the double knockout mice on 
the control diet or the HFD. These data suggest hypersen-
sitivity to these hormones, although no changes in insulin 
and leptin sensitivity were observed in B1B2KO mice. On 
the other hand, B1B2KO mice showed less glycemia and 
increased glucose tolerance after treatment with the HFD. 
We believe the mechanisms underlying these findings may 
be related to the control of energy intake and its expenditure. 
Indeed, energy expenditure is increased in B1B2KO mice, 
as suggested by the feed efficiency data. Studies analyzing 
the impact of B1 receptor on metabolism have found that 
B1KO mice benefit from deletion of the B1 receptor, with 
better leptin and insulin sensitivity.16,17 In agreement with 
this, blockade of the B1 receptor by the specific inhibitor 
SSR240612 reverted insulin and glucose concentrations to 
baseline levels in insulin-resistant glucose-fed rats.19
By analyzing the B2 receptor knockout (B2KO) mouse 
phenotype, our group has found decreased serum insulin lev-
els and increased glucose uptake after stimulation with insulin 
(unpublished data). Schweitzer et al28 reported that B2KO 
mice also have lower serum insulin levels, but show decreased 
glucose tolerance. Conversely, it has been shown that B2KO 
mice have higher serum insulin levels and are resistant to 
the effects of insulin on mediating glucose uptake.29 Taking 
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these data together, the role of the B2 receptor in glucose 
uptake remains controversial. We can conclude that disrup-
tion of this receptor leads to significant alterations in glucose 
 homeostasis, probably by  compensatory  mechanisms pro-
moted by other related genes. Indeed, recent gene expression 
data from microarray analysis of B2KO mice have shown 
dysregulation of several genes related to pathological path-
ways involved in endothelial injury, oxidative stress, insulin 
and leptin metabolism, and the inflammatory process.30 
Therefore, we propose that deletion of the B2 receptor in 
mice regulates expression of not only the B1 receptor,20 but 
also genes linked to insulin and glucose homeostasis. In 
agreement with this idea, we believe that disruption of the 
B1 receptor in mice leads not only to altered expression of 
B2 receptor,21 but also other genes related to control of the 
energy balance. In this scenario, our double knockout model 
shows that metabolic  parameters measured in the B1B2KO 
mice were not  exclusively  dependent on B1 or B2 receptor 
regulation, indicating that ablation of the B1 and/or B2 recep-
tor might also have a profound impact on several other gene 
pathways related to disorders of metabolism.
To determine the link between abrogation of KKS and 
genes involved in metabolic homeostasis, we analyzed gene 
expression of proteins related to insulin resistance and the 
inflammatory process. We focused on  inflammatory genes 
because the B1 receptor plays an important role in the 
immune response in many disorders.31–33 Thus, we measured 
gene expression of TNF-α and CRP, given that these proteins 
are present in elevated concentrations in insulin-resistant and 
obese individuals. In these cases, white adipose tissue and 
skeletal muscle are the main sources of TNF-α,34,35 which 
is directly related to impaired glucose uptake and insulin 
resistance mechanisms via activation of nuclear factor 
kappa B and IKKβ signaling.36 Here we found that B1B2KO 
 HFD-treated mice had decreased TNF-α mRNA expres-
sion in white adipose tissue and skeletal muscle.  Similarly, 
increased CRP levels, with liver as the main source, are 
related to impaired insulin resistance.16 We observed that CRP 
mRNA  expression was decreased in the liver of the B1B2KO 
mouse after the HFD. Recently, Diaz et al  demonstrated that 
blockade of the B1 receptor is able to reverse inflammatory 
biomarkers related to insulin  resistance in insulin-resistant 
glucose-fed rats.19 These findings suggest that reduced mRNA 
expression of TNF-α and CRP could be related to deletion 
of the B1 receptor in B1B2KO mice. Absence of the pro-
inflammatory B1 receptor could be mandatory to modify the 
expression of inflammatory genes involved in the pathology 
of insulin resistance.
Accordingly, in order to observe the effect of pharma-
cological blockade of the B1 and B2 receptors, we treated 
WT animals with specif ic antagonists, ie, R-715 and 
 HOE-140. No change in mRNA expression was observed 
after  pharmacological treatment for leptin, TNF-α, and CRP 
gene expression in white adipose tissue, skeletal muscle, 
or the liver. Conversely, leptin mRNA expression was not 
decreased in white adipose tissue after treatment with specific 
antagonists, indicating that the decreased baseline leptin 
levels found in B1B2KO mice probably resulted from more 
profound and prolonged inactivation of kinin receptors.
In conclusion, we found that a deficiency of B1 and B2 
receptors protects against obesity induced by an HFD and 
promotes a decrease in circulating levels of insulin and leptin. 
In addition, deletion of both B1 and B2 receptors has specific 
consequences with regard to mechanisms  involving glucose 
homeostasis, ie, improving glucose tolerance. We propose 
that compensatory effects, as a consequence of disruption 
of the KKS, could dysregulate expression of  inflammatory 
genes related to metabolic disorders such as insulin  resistance. 
Therefore, our findings reinforce the role of the KKS in 
metabolism by showing that B1 and B2 receptor regulation 
is crucial for glucose tolerance control in mice, and suggest 
that new drugs focused on the KKS might be effective as 
therapeutic tools for conditions related to obesity, such as 
insulin resistance and diabetes.
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